Moderate and severe COVID-19 survivors show progressive cardiovascular injury, especially right ventricular dysfunction, with FeNO and ET-1 as effective prognostic biomarkers.
Do FeNO and ET-1 serve as prognostic biomarkers for progressive cardiovascular injury in moderate and severe COVID-19 survivors?
FeNO and ET-1 are effective prognostic biomarkers that, alongside echocardiography, can help risk-stratify COVID-19 survivors for progressive right ventricular and cardiovascular deterioration.
Absolute Event Rate: 0% vs 0%
Moderate and severe COVID-19 survivors exhibit progressive cardiovascular deterioration, particularly affecting right ventricular function. FeNO and ET-1 serve as severity-specific prognostic biomarkers and demonstrate excellent discriminative performance, supporting their integration into risk stratification protocols for COVID-19 survivors.
Süleymanoğlu et al. (Sun,) reported a other. Moderate and severe COVID-19 survivors show progressive cardiovascular injury, especially right ventricular dysfunction, with FeNO and ET-1 as effective prognostic biomarkers.